Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Excretion Clear all

Conditions: Autistic Disorder, Enuresis
Interventions: Moisture Pager Intervention for Toilet Training, Standard of Care; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 10 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Rochester, New York • Columbus, Ohio • Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: [14C]-BGB-3111, BGB-3111; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Nocturnal Enuresis
Interventions: Ninjamas Pyjama Pants, Participant's Overnight Current Standard of Care; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: [14C]-Fosgonimeton; Drug
Lead sponsor: LeonaBio; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: LY2886721; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Dialysis, Pharmacokinetics
Interventions: PD-0332334; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Migraine
Interventions: Galcanezumab, Placebo; Drug · Other
Lead sponsor: Diamond Headache Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriasis
Interventions: 12-week elimination diet; Other
Lead sponsor: University of Michigan; Other
Eligibility: 12 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Thyroid Cancer
Interventions: Skin Biopsy; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteer
Interventions: varegacestat; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Nocturnal Enuresis, Anemia, Sickle Cell
Interventions: Desmopressin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 8 Years to 21 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Eosinophilic Esophagitis, Eosinophilic Gastrointestinal Disorders (EGIDs)
Interventions: 1 Food Elimination Diet, 4 Food Elimination Diet, 4 Food Elimination Diet (post 1FED failure), Fluticasone Propionate, 800 mcg twice daily (post 4FED failure); Other · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 17 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: EDP-938; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Obesity
Interventions: Food Allergy Elimination + Willis Exercise; Behavioral
Lead sponsor: Galveston Clinical Research Foundation; Other
Eligibility: 20 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Healthy Volunteers
Interventions: [14C]-olinciguat; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Bedwetting
Interventions: TENS; Device
Lead sponsor: Rajeev Chaudhry; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Refractive Error
Interventions: ELITA System; Device
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California • Draper, Utah

Conditions: Healthy, Enteric Hyperoxaluria
Interventions: FB-001, Placebo; Biological
Lead sponsor: Federation Bio Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: BMS-955176; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Macromastia (Symptomatic)
Interventions: Pectoral II Nerve Block, Post Operative Pain Relievers; Procedure · Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Anemia of Chronic Kidney Disease
Interventions: JTZ-951, 14C-JTZ-951; Drug
Lead sponsor: Akros Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
Interventions: Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Thearubigins, Theaflavins, Procyanidin Dimer B2 (DB2), (-)-Epigallocatechin-3-O-gallate (EGCG), (-)-Epicatechin-3-O-gallate (ECG), (-)-Epicatechin (EC), (-)-Epigallocatechin (EGC), Control; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 25 Years to 60 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Davis, California

Search by objective public record fields.

Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Overnight Pant Study for Children With Nocturnal Enuresis

A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017)

Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

The Role of Food Sensitivity in Psoriasis

The Effect of Thyroid Hormone on Drug Elimination in Cancer Patients

A Phase 1 Mass Balance Study of Varegacestat

Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids

Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects

Food Allergen Eliminations and Combined Protocols for Obesity Reduction: a Preliminary Comparison Study

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Hand & Foot Nocturnal Enuresis TENS Study

A PHASED, PROSPECTIVE, MULTI-CENTER STUDY OF THE ELITA SYSTEM

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

Pectoral Block in Breast Reduction for Pain Control

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure

Absorption, Metabolism and Excretion of Dietary Polyphenolic Bioactives in Humans